RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA
Clinical trials for RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer patients in major drug trial
Disease control Recruiting nowThis study is testing the safety and dosing of a new oral drug called lisaftoclax, both by itself and combined with other cancer drugs, for people with acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The goal is to find the safest and most effe…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough blood cancers: experimental combo targets resistant leukemia
Disease control Recruiting nowThis study is testing whether a new three-drug combination can help control acute myeloid leukemia (AML) that has returned or hasn't responded to previous treatments. The trial will enroll 72 adults with relapsed or refractory AML to receive the drug combination and closely monit…
Matched conditions: RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Mar 17, 2026 13:08 UTC